Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $100.1852W HIGH $145.00
Volume
1.00 M
Value Traded
78.40 M
Short % Float
9.53%
+0.06%Week
-8.5%1 Month
-8.5%3 Month
+4.9%6 Month
-66.9%5 Year
+30,579.24%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.26 B
EPS (TTM)
-24.35
P/E Ratio
-
Ent. Value
7.83 B
Total Shares
42.35 M
Float Shares
42.01 M
Insiders
0.85%
Institutions
113.53%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TFX Catalyst Timeline
Dated clinical, regulatory and corporate events for Teleflex Incorporated
Catalyst Timeline
Dated clinical, regulatory & corporate events for Teleflex Incorporated
2Total events
0Upcoming
1Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How TFX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 84%
Small Cap(rank 553 of 658)
Percentile Rank
Teleflex Incorporated faces pipeline headwinds (25/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every TFX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| UroLift System | benign prostatic hyperplasia (BPH) | 2025-05-15 | 70% of men randomized to the medication treatment arm eventually chose to crossover to the UroLift™ System.Read More | Teleflex Showcases New Clinical Data Presented at the 2025 American Urological Association (AUA) Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ryu JaewonDirector | Grant/Award | 1,090 4,817 held | $0.00 | 05/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TFX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PFM HEALTH SCIENCES, LP | 0.9 % (-25 %) | 10.10 M | 79.71 K | -22.16% ( -22.69 K) |
TFX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TFX ranks across every disease it competes in
Competitive Position is a premium feature
See how TFX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTFX News
TFXTeleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology
Teleflex Incorporated announced a peer-reviewed study published in the American Journal of Infection Control. The study found that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology significantly reduced the risk of central line-associated bloodstream infections (CLABSIs) by 70% compared to standard catheters. This finding highlights the effectiveness of the technology in improving patient safety.
Read more →TFXTeleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
Teleflex Incorporated has appointed Sean M. Salmon to its Board of Directors, effective September 8, 2026. Salmon brings over 30 years of leadership experience in the medical device and pharmaceutical sectors, including more than 20 years at Medtronic. His expertise is anticipated to strengthen Teleflex's strategic direction.
Read more →TFXTeleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026
Teleflex Incorporated will present its innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026 in Copenhagen. This event underscores the company's dedication to advancing healthcare technologies. The stent system is backed by the BIONETIC-TRA study, emphasizing its significance in medical advancements.
Read more →TFXTeleflex Announces Quarterly Dividend
Teleflex Incorporated has announced a quarterly cash dividend of $0.34 per share, payable on September 30, 2026. Shareholders of record as of August 14, 2026, will receive this dividend. This decision highlights the company's ongoing commitment to providing returns to its investors.
Read more →TFXTeleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook
Teleflex Incorporated reported its second quarter financial results for 2026, showing a significant revenue increase of 28.9% year-over-year, reaching $570.3 million. However, the GAAP diluted earnings per share (EPS) fell to $0.96 from $1.54 in the same period last year. The company also provided an optimistic outlook for the full year 2026.
Read more →TFXTeleflex Medical OEM Launches as INGENYX to Empower Tomorrow’s MedTech Innovators
Teleflex Medical OEM has launched as INGENYX following its acquisition by Montagu and Kohlberg. This transition allows INGENYX to focus on enhancing engineering capabilities and innovation in medical device manufacturing. The company aims to support clients in navigating complex product development challenges while maintaining continuity in expertise and customer commitment.
Read more →TFXTeleflex Completes Strategic Divestiture of OEM Business for $1.5 Billion
Teleflex Incorporated has successfully completed the divestiture of its OEM business to Montagu and Kohlberg for $1.5 billion in cash. This strategic move is part of Teleflex's transformation strategy, allowing the company to concentrate on its core operations and enhance its financial flexibility. The transaction is seen as a significant milestone for the company.
Read more →TFXTeleflex Announces FDA BLA Approval of EZPLAZ™ Freeze Dried Plasma
Teleflex Incorporated has received FDA approval for its EZPLAZ™ Freeze Dried Plasma, designed for transfusion in adults experiencing bleeding-related conditions. This approval signifies an important advancement in medical technology, particularly for patients requiring plasma coagulation factors. The product aims to enhance treatment options for uncontrolled bleeding.
Read more →TFXTeleflex Announces Second Quarter 2026 Earnings Conference Call Information
Teleflex Incorporated will hold a conference call on August 6, 2026, to discuss its second quarter financial results and provide an operational update. The call will begin at 8:00 a.m. Eastern Time and will be accessible via a pre-registration link and a live audio webcast on the company's website. An audio replay will be available after the call.
Read more →TFXTeleflex Awarded National Central Venous Access Agreement with Premier, Inc.
Teleflex Incorporated has secured a national group purchasing agreement with Premier, Inc. This agreement, effective July 1, 2026, allows Premier members to access pre-negotiated pricing on various Teleflex central venous access products. The deal includes short-term catheters and arterial catheter products, enhancing Teleflex's market presence.
Read more →TFXTeleflex Publishes 2025 Global Impact Report
Teleflex has published its 2025 Global Impact Report, which outlines the company's initiatives and commitments towards sustainability and social responsibility. The report highlights various strategies aimed at improving global health and environmental stewardship. However, specific details on the content of the report are not provided in the article.
Read more →TFXTeleflex Initiates Enrollment in Global BIOMAG™‑III Pivotal Trial of Freesolve™ Resorbable Magnesium Scaffold
Teleflex has announced the initiation of enrollment in the global BIOMAG-III pivotal trial for its Freesolve resorbable magnesium scaffold. This trial aims to evaluate the safety and efficacy of the scaffold in patients. The move reflects Teleflex's dedication to advancing innovative medical solutions.
Read more →TFXFour‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)
The article discusses the presentation of the four-year results from the BIOMAG-I study at EuroPCR. The study confirms the long-term safety and sustained performance of the Freesolve Resorbable Magnesium Scaffold. Further details about the findings and implications for clinical practice were not provided.
Read more →TFXTELEFLEX INCORPORATED ANNOUNCES PRICING OF $500 MILLION SENIOR NOTES OFFERING
Teleflex Incorporated has announced the pricing of its private offering of $500 million in senior notes with an interest rate of 5.875%, set to mature in 2032. The offering is anticipated to close on June 15, 2026, and will be backed by its wholly-owned domestic subsidiaries. The funds raised will be used primarily to redeem existing senior notes due in 2027. The transaction is designated for qualified institutional buyers and certain non-U.S. persons, adhering to regulatory exemptions for public offerings.
Read more →TFXTeleflex Incorporated Announces Pricing of $500 Million Senior Notes Offering
Teleflex Incorporated has announced the pricing of a $500 million senior notes offering. The offering is part of the company's strategy to raise capital. Further details regarding the terms and conditions of the offering have not been disclosed in the article.
Read more →TFXTeleflex Incorporated Announces Private Offering of $500 Million of Senior Notes Due 2032
Teleflex Incorporated has announced a private offering of $500 million in senior notes due in 2032. The offering aims to strengthen the company's financial position. Further details regarding the use of proceeds or interest rates have not been disclosed in the announcement.
Read more →TFXTeleflex Showcases New Clinical Data at Leading Urological Congresses Highlighting Patient Experience Advantages of the UroLift™ System and Long-Term Toxicity Reduction with Barrigel™ Rectal Spacer
Teleflex has unveiled new clinical data at prominent urological congresses, emphasizing the benefits of the UroLift™ System in enhancing patient experiences. Additionally, the Barrigel™ Rectal Spacer has been noted for its effectiveness in reducing long-term toxicity. These findings could significantly impact treatment approaches in urology.
Read more →TFX▲ +6.9%on this news
Teleflex Reports First Quarter Financial Results and Full Year 2026 Outlook
Teleflex Incorporated reported a 32.3% increase in revenue for Q1 2026, totaling $548.3 million. Despite a loss in GAAP diluted EPS, the company maintained its revenue growth guidance for the year. The interim CEO highlighted progress in their transformation plan and the anticipated closure of strategic divestitures. The company aims to return capital to shareholders while reducing debt.
Read more →TFX▼ -7%on this news
Teleflex Appoints Jason Weidman as President and CEO
Teleflex Incorporated has appointed Jason Weidman as President and CEO, effective June 8, 2026. Weidman, who has over 25 years of experience in the medical technology sector, succeeds Stuart Randle, who will remain on the Board of Directors. The leadership change comes as Teleflex aims to transform its portfolio and enhance growth following significant financial strategies.
Read more →TFXTeleflex Announces First Quarter 2026 Earnings Conference Call Information
Teleflex Incorporated will hold a conference call on May 7, 2026, at 8:00 a.m. ET to discuss its first quarter financial results and provide an operational update. Participants can pre-register for the call or access it via a live audio webcast on the company's website. An audio replay will be available later that day.
Read more →About Teleflex Incorporated
Headquarters550 E SWEDESFORD RD, WAYNE, PA, 19087
BIOPHARMAWATCH ELITE PLUS
Trade the next TFX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime